APR 12, 2017 12:00 PM PDT
PAMA: The First Reporting Period is Over. What Does This Legislation Mean for Laboratorie
Presented at the Molecular Diagnostics 2017 Virtual Event
2 1 98

  • Principal at Roger D. Klein, MD JD Consulting, Cleveland Clinic, Chair, Professional Relations Committee, Association for Molecular Pathology (AMP); Medical Director, Molecular Oncology
      Roger D. Klein, M.D., J.D., serves as Medical Director of Molecular Oncologyo at Bloodcenter Of Wisconsin, Inc. Dr. Klein lead the development of BloodCenter of Wisconsin's Diagnostic Laboratories' newest initiative, which will focus on DNA- and RNA-based testing for evaluation of cancer patients.Dr. Klein is a national leader in the advancement of policies related to the implementation of genetic and genomic testing. Specifically, as relates to this webinar, he has been actively engaged in CPT coding, coverage and reimbursement issues with the College of American Pathologists, the Association for Molecular Pathology, and the American Medical Association Molecular Pathology CPT Advisory Group, and governmental panels such as the Medicare Evidence Development and Coverage Advisory Committee. He has played a leading role in the creation and maintenance of the Molecular Pathology section in the CPT Manual.


    This presentation describes the new process by which the Centers for Medicare and Medicaid Services (CMS) will establish the prices the Agency pays for clinical diagnostic laboratory tests.  This revolutionary approach was
    mandated by Congress in the clinical laboratory provisions contained within Section 216 of the Protecting Access to Medicare Act of 2014.  In his talk Dr. Klein will discuss this legislation, accompanying CMS regulations, and their
    potential impacts on the laboratory industry

    Show Resources
    Loading Comments...